CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding CNS Pharmaceuticals, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 19 | 10 | −9 |
| Shares | 972.6K | 144.2K | −828.5K (−85.2%) |
| Value | $351.0K | $227.8K | −$123.3K (−35.1%) |
New holders (3)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Anson Funds Management LP | 141,398 | $223.4K | 0.03% |
| UBS Group AG | 2,629 | $4.15K | 0.00% |
| Parallel Advisors, LLC | 1 | $2 | 0.00% |
Sold out (12)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Armistice Capital, LLC | 471,000 | $170.5K |
| Virtu Financial LLC | 94,246 | $34.0K |
| Citadel Advisors LLC | 91,034 | $33.0K |
| Smith Anglin Financial, LLC | 90,332 | $32.7K |
| Vanguard Group Inc | 58,369 | $21.1K |
| Geode Capital Management, LLC | 28,254 | $10.2K |
| Jane Street Group, LLC | 27,388 | $9.91K |
| State Street Corp | 22,556 | $8.16K |
| Two Sigma Securities, LLC | 21,806 | $7.89K |
| HRT Financial LP | 21,898 | $7.00K |
| FSM Wealth Advisors, LLC | 19,084 | $6.91K |
| XTX Topco Ltd | 18,729 | $6.78K |